GH
Guardant Health, Inc.
Is GH Halal?
Cancer liquid-biopsy diagnostics are permissible healthcare activity, but current convertible debt, liquidity and receivables screens fail decisively.
What You Should Know
Guardant Health, Inc. develops blood-based cancer diagnostics and screening tests including Guardant360 and Shield. Its March 31, 2026 Form 10-Q reports $1,915.291 million of assets, $1,503.471 million of convertible debt, $989.291 million of cash, $1,118.284 million of available-for-sale debt securities, $137.404 million of accounts receivable and $301.665 million of first-quarter revenue. Debt/assets is 78.50%, liquidity/assets is 110.04%, receivables-plus-cash/assets is 58.83% and investment income interest/revenue is 3.70%. Medical diagnostics are generally permissible, but the current quantitative result is doubtful.
⚠️ Concerns
- •Debt/assets is 78.50%, above the examined 33.333% asset-based limit
- •Liquidity/assets is 110.04%, above the examined limits
- •Receivables-plus-cash/assets is 58.83%, above the examined limits
- •Investment income interest is 3.70% of revenue; purification treatment remains methodology-specific
- •Convertible debt and cash/security balances can change the verdict materially
Current quantitative Sharia screen
Based on 10-Q figures for the period ended 2026-03-31; calculated 2026-07-15.
1,503.471 / 1,915.291
2,107.575 / 1,915.291
1,126.695 / 1,915.291
11.151 / 301.665
- Financial
- Fails
- Overall
- Fails
Debt/assets is 78.50%, liquidity/assets is 110.04% and receivables plus cash/assets is 58.83%, above the examined limits; interest income/revenue is 3.70%.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 78.50%, liquidity/assets is 110.04% and receivables plus cash/assets is 58.83%, above the examined MSCI limits; interest income/revenue is 3.70%.
- Financial
- Fails
- Overall
- Fails
Debt/assets is 78.50% and liquidity/assets is 110.04%, above the examined Malaysia SAC limits; this is not an official classification.
- Financial
- Not calculated
- Overall
- Fails
A licensed historical market-cap series is not stored; the asset-based screens fail decisively on debt and liquidity.
Business-activity disclosure
Guardant develops blood-based cancer diagnostics and screening tests. Medical diagnostics are generally permissible, while test use, customer, collaboration and product-level disclosure remains methodology-dependent.
Limitation: The filing does not allocate every diagnostic, customer or collaboration revenue stream into a universal prohibited-activity numerator.
Purification
Guardant discloses $11.151 million of investment income interest, but no scholar-approved purification percentage is inferred.
Inputs, assumptions and primary sources
- Amounts are USD millions from Guardant Health's March 31, 2026 Form 10-Q.
- Debt is $1,503.471 million of noncurrent convertible debt; operating leases are excluded.
- Cash and cash equivalents are $989.291 million. Available-for-sale debt securities are $1,118.284 million and are included as identifiable interest-bearing securities; restricted cash is not added again.
- Accounts receivable, net is $137.404 million and first-quarter revenue is $301.665 million.
- Investment income interest is $11.151 million; the filing does not provide a universal prohibited-revenue numerator for diagnostics, screening or collaborations.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →